BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25690281)

  • 1. XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population.
    Dai Q; Luo H; Li XP; Huang J; Zhou TJ; Yang ZH
    Mutagenesis; 2015 May; 30(3):441-9. PubMed ID: 25690281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
    Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
    Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
    Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
    Sun K; Gong A; Liang P
    Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
    Sun Y; Wu Y; Li W; Kong Z; Zou X
    Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The polymorphisms of miRNA-binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case-control study.
    Zhang Q; Zheng X; Li X; Sun D; Xue P; Zhang G; Xiao M; Cai Y; Jin C; Yang J; Wu S; Lu X
    Cancer Med; 2018 Apr; 7(4):1264-1274. PubMed ID: 29516665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
    Yin Z; Zhou B; He Q; Li M; Guan P; Li X; Cui Z; Xue X; Su M; Ma R; Bai W; Xia S; Jiang Y; Xu S; Lv Y; Li X
    BMC Cancer; 2009 Dec; 9():439. PubMed ID: 20003463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS polymorphisms are associated with survival of CRC in Chinese population.
    Dai Q; Wei HL; Huang J; Zhou TJ; Chai L; Yang ZH
    Tumour Biol; 2016 Apr; 37(4):4727-34. PubMed ID: 26515332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
    Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
    Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.
    van Huis-Tanja LH; Kweekel DM; Lu X; Franken K; Koopman M; Gelderblom H; Antonini NF; Punt CJ; Guchelaar HJ; van der Straaten T
    Mutat Res; 2014 Jan; 759():37-44. PubMed ID: 24220697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
    Figg WD; Chau CH; Madan RA; Gulley JL; Gao R; Sissung TM; Spencer S; Beatson M; Aragon-Ching J; Steinberg SM; Dahut WL
    Clin Genitourin Cancer; 2013 Sep; 11(3):229-37. PubMed ID: 23684781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.